AAPL   318.25 (+0.04%)
MSFT   181.40 (-0.23%)
FB   225.46 (-1.61%)
AMZN   2,401.10 (-0.39%)
NVDA   339.48 (-0.45%)
BABA   199.49 (-0.84%)
MU   46.47 (-6.03%)
GE   6.78 (-7.00%)
TSLA   805.81 (-1.76%)
AMD   51.74 (-1.90%)
F   5.85 (-2.99%)
GILD   75.32 (+0.56%)
DIS   116.75 (-3.93%)
NFLX   413.44 (-1.54%)
BAC   24.86 (-4.31%)
AAPL   318.25 (+0.04%)
MSFT   181.40 (-0.23%)
FB   225.46 (-1.61%)
AMZN   2,401.10 (-0.39%)
NVDA   339.48 (-0.45%)
BABA   199.49 (-0.84%)
MU   46.47 (-6.03%)
GE   6.78 (-7.00%)
TSLA   805.81 (-1.76%)
AMD   51.74 (-1.90%)
F   5.85 (-2.99%)
GILD   75.32 (+0.56%)
DIS   116.75 (-3.93%)
NFLX   413.44 (-1.54%)
BAC   24.86 (-4.31%)
AAPL   318.25 (+0.04%)
MSFT   181.40 (-0.23%)
FB   225.46 (-1.61%)
AMZN   2,401.10 (-0.39%)
NVDA   339.48 (-0.45%)
BABA   199.49 (-0.84%)
MU   46.47 (-6.03%)
GE   6.78 (-7.00%)
TSLA   805.81 (-1.76%)
AMD   51.74 (-1.90%)
F   5.85 (-2.99%)
GILD   75.32 (+0.56%)
DIS   116.75 (-3.93%)
NFLX   413.44 (-1.54%)
BAC   24.86 (-4.31%)
AAPL   318.25 (+0.04%)
MSFT   181.40 (-0.23%)
FB   225.46 (-1.61%)
AMZN   2,401.10 (-0.39%)
NVDA   339.48 (-0.45%)
BABA   199.49 (-0.84%)
MU   46.47 (-6.03%)
GE   6.78 (-7.00%)
TSLA   805.81 (-1.76%)
AMD   51.74 (-1.90%)
F   5.85 (-2.99%)
GILD   75.32 (+0.56%)
DIS   116.75 (-3.93%)
NFLX   413.44 (-1.54%)
BAC   24.86 (-4.31%)
Log in

LON:SBTXSkinbiotherapeutics Share Price, Forecast & News

GBX 17.25
+0.08 (+0.47 %)
(As of 05/28/2020 04:00 PM ET)
Add
Compare
Today's Range
17
Now: GBX 17.25
17.40
50-Day Range
7
MA: GBX 14.08
18.90
52-Week Range
5
Now: GBX 17.25
26
Volume244,944 shs
Average Volume261,826 shs
Market Capitalization£22.09 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
SkinBioTherapeutics plc, a life science company, engages in the research and development of lysates derived from the human microbiome on skin. It is developing pre-clinical product application, SkinBiotix, a cosmetic cream for skin health, as well as for applications in infection control and eczema. The company was formerly known as Skinbiotix Ltd. SkinBioTherapeutics plc was founded in 2016 and is based in Macclesfield, the United Kingdom.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.44 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-161-4682760

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Cash FlowGBX 1.96 per share
Book ValueGBX 2.40 per share

Profitability

Miscellaneous

Employees6
Market Cap£22.09 million
Next Earnings DateN/A
OptionableNot Optionable

Receive SBTX News and Ratings via Email

Sign-up to receive the latest news and ratings for SBTX and its competitors with MarketBeat's FREE daily newsletter.

Skinbiotherapeutics (LON:SBTX) Frequently Asked Questions

How has Skinbiotherapeutics' stock been impacted by COVID-19 (Coronavirus)?

Skinbiotherapeutics' stock was trading at GBX 8.50 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, SBTX shares have increased by 102.9% and is now trading at GBX 17.25. View which stocks have been most impacted by Coronavirus.

How were Skinbiotherapeutics' earnings last quarter?

Skinbiotherapeutics PLC (LON:SBTX) announced its earnings results on Tuesday, March, 3rd. The company reported ($0.64) earnings per share (EPS) for the quarter. View Skinbiotherapeutics' earnings history.

Has Skinbiotherapeutics been receiving favorable news coverage?

Media coverage about SBTX stock has trended very negative on Thursday, InfoTrie Sentiment reports. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Skinbiotherapeutics earned a media sentiment score of -3.8 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutSkinbiotherapeutics.

Who are some of Skinbiotherapeutics' key competitors?

What other stocks do shareholders of Skinbiotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Skinbiotherapeutics investors own include Anglo Pacific Group (APF), Avacta Group (AVCT), Inspired Energy (INSE), OptiBiotix Health (OPTI), LB-Shell (LBP), Namibian Resources (AAOG), Big Sofa Technologies Group (BST), Concepta (CPT), Fresnillo (FRES) and Shield Therapeutics (STX).

Who are Skinbiotherapeutics' key executives?

Skinbiotherapeutics' management team includes the following people:
  • Dr. Catherine O'Neill, CEO, Chief Scientific Officer & Director
  • Mr. Douglas John Quinn, CFO, Company Sec. & Director
  • Mr. Stuart John Ashman, Exec. Director (Age 52)

What is Skinbiotherapeutics' stock symbol?

Skinbiotherapeutics trades on the London Stock Exchange (LON) under the ticker symbol "SBTX."

How do I buy shares of Skinbiotherapeutics?

Shares of SBTX and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Skinbiotherapeutics' stock price today?

One share of SBTX stock can currently be purchased for approximately GBX 17.25.

How big of a company is Skinbiotherapeutics?

Skinbiotherapeutics has a market capitalization of £22.09 million. Skinbiotherapeutics employs 6 workers across the globe.

What is Skinbiotherapeutics' official website?

The official website for Skinbiotherapeutics is www.skinbiotherapeutics.com.

How can I contact Skinbiotherapeutics?

Skinbiotherapeutics' mailing address is 15 1 Silk House, Park Green, MACCLESFIELD, SK11 7QJ, United Kingdom. The company can be reached via phone at +44-161-4682760.

This page was last updated on 5/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.